Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH, Markowitz M.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2007.43.12.1146063 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för raltegravir. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
34 hitsDihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.
Pace P, Di Francesco ME, Gardelli C, Harper S, Muraglia E, Nizi E, Orvieto F, Petrocchi A, Poma M, Rowley M, Scarpelli R, Laufer R, Gonzalez Paz O, Monteagudo E, Bonelli F, Hazuda D, Stillmock KA, Summa V.
J Med Chem · journal article · DOI 10.1021/jm070027uExpanded access drug profile: raltegravir (RAL, MK-0518).
Colquitt AR, Pham PA.
Hopkins HIV Rep · newspaper article; journal articleAntiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H.
J Acquir Immune Defic Syndr · multicenter study; randomized controlled trial; journal article · DOI 10.1097/qai.0b013e31802b4956